Carl H. June

Center for Cellular Immunotherapies, University of Pennsylvania

Affiliated withUniversity of Pennsylvania

Research Area

Biography

Carl H. June has not added Biography.
If you are Carl H. June and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 2	Year
Publication title Cited by 19	2021
Publication title	2026

Other Publications

Article	Year
Mesothelin expression is associated with poor outcomes in breast cancer. Breast cancer research and treatment\| PubMed ID: 25193277	2014
Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England journal of medicine\| PubMed ID: 25317870	2014
Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer immunology research\| PubMed ID: 25600436	2015
Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Science translational medicine\| PubMed ID: 25696001	2015
The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 25712684	2015
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer research\| PubMed ID: 25979873	2015
High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 26071480	2015
Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 26188068	2015
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature medicine\| PubMed ID: 26193344	2015
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer research\| PubMed ID: 26330166	2015
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science translational medicine\| PubMed ID: 26333935	2015
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. The New England journal of medicine\| PubMed ID: 26352815	2015
T cell engineering as therapy for cancer and HIV: our synthetic future. Philosophical transactions of the Royal Society of London. Series B, Biological sciences\| PubMed ID: 26416683	2015
Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood\| PubMed ID: 26563133	2016
Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 26740110	2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood\| PubMed ID: 26813675	2016
Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. American journal of hematology\| PubMed ID: 26858124	2016
T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. Oncoimmunology\| PubMed ID: 26942053	2016
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer research\| PubMed ID: 26979791	2016
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. Journal for immunotherapy of cancer\| PubMed ID: 26981245	2016
Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. Journal of immunological methods\| PubMed ID: 27049586	2016
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer discovery\| PubMed ID: 27076371	2016
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 27084741	2016
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood\| PubMed ID: 27166358	2016
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity\| PubMed ID: 27332733	2016
Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy. Oncoimmunology\| PubMed ID: 27467909	2016
miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. Blood\| PubMed ID: 27485827	2016
Rethinking the Regulatory Infrastructure for Human Gene Transfer Clinical Trials. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 27506378	2016
Engineered T cells: the promise and challenges of cancer immunotherapy. Nature reviews. Cancer\| PubMed ID: 27550819	2016
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. The Journal of clinical investigation\| PubMed ID: 27571406	2016
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Critical care medicine\| PubMed ID: 27632680	2017
A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? Pathogens & immunity\| PubMed ID: 27668293	2016
Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 27815355	2017
Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety. Immunity\| PubMed ID: 27851918	2016
Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus. PLoS pathogens\| PubMed ID: 27855210	2016
Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. Cytotherapy\| PubMed ID: 27887864	2017
Driving gene-engineered T cell immunotherapy of cancer. Cell research\| PubMed ID: 28025979	2017
PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood\| PubMed ID: 28031179	2017
The Principles of Engineering Immune Cells to Treat Cancer. Cell\| PubMed ID: 28187291	2017
A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget\| PubMed ID: 28199983	2017
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood\| PubMed ID: 28246194	2017
Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation. Protein & cell\| PubMed ID: 28523432	2017
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer discovery\| PubMed ID: 28576927	2017
Ibrutinib treatment improves T cell number and function in CLL patients. The Journal of clinical investigation\| PubMed ID: 28714866	2017
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science translational medicine\| PubMed ID: 28724573	2017
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood\| PubMed ID: 28935694	2017
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18. Cell reports\| PubMed ID: 28954221	2017
Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 28970045	2018
Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer. Current hematologic malignancy reports\| PubMed ID: 29039115	2017
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. Cancer immunology research\| PubMed ID: 29109077	2017
Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 29203150	2018
Human CD26 T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. Nature communications\| PubMed ID: 29213079	2017
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. The New England journal of medicine\| PubMed ID: 29226764	2017
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI insight\| PubMed ID: 29321369	2018
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. The New England journal of medicine\| PubMed ID: 29385370	2018
Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12. JCI insight\| PubMed ID: 29467322	2018
CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro-oncology\| PubMed ID: 29509936	2018
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Gastroenterology\| PubMed ID: 29567081	2018
CAR T cell immunotherapy for human cancer. Science (New York, N.Y.)\| PubMed ID: 29567707	2018
Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager. Cancer immunology research\| PubMed ID: 29588319	2018
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI insight\| PubMed ID: 29618658	2018
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Science translational medicine\| PubMed ID: 29643231	2018
Immunotherapy for Breast Cancer: Current and Future Strategies. Current surgery reports\| PubMed ID: 29657904	2017
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI insight\| PubMed ID: 29669947	2018
The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. Scientific reports\| PubMed ID: 29674640	2018
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature medicine\| PubMed ID: 29713085	2018
Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 29784587	2018
Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 29807781	2018
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature\| PubMed ID: 29849141	2018
Driving cars to the clinic for solid tumors. Gene therapy\| PubMed ID: 29880908	2018
Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. Blood\| PubMed ID: 29925499	2018
Chimeric Antigen Receptor Therapy. The New England journal of medicine\| PubMed ID: 29972754	2018
Reducing Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. Cancer immunology research\| PubMed ID: 30030295	2018
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 30190371	2018
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature medicine\| PubMed ID: 30275568	2018
Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas. Molecular therapy oncolytics\| PubMed ID: 30306125	2018
CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia\| PubMed ID: 30315238	2018
Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy\| PubMed ID: 30385043	2018
Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology. Frontiers in immunology\| PubMed ID: 30416506	2018
Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 30446589	2019
Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma. British journal of cancer\| PubMed ID: 30478409	2019
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. Journal for immunotherapy of cancer\| PubMed ID: 30514386	2018
Emerging Cellular Therapies for Cancer. Annual review of immunology\| PubMed ID: 30526160	2019
Delivery technologies for cancer immunotherapy. Nature reviews. Drug discovery\| PubMed ID: 30622344	2019
iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity. Genome biology\| PubMed ID: 30654827	2019
Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells. CPT: pharmacometrics & systems pharmacology\| PubMed ID: 30848084	2019
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. The Journal of clinical investigation\| PubMed ID: 30896447	2019
Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8 T cells and impede CAR T-cell efficacy. Blood\| PubMed ID: 31076448	2019
Boosting engineered T cells. Science (New York, N.Y.)\| PubMed ID: 31296754	2019
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell\| PubMed ID: 31398344	2019
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 31420241	2019
Emerging Use of CRISPR Technology - Chasing the Elusive HIV Cure. The New England journal of medicine\| PubMed ID: 31509669	2019
Targeting cardiac fibrosis with engineered T cells. Nature\| PubMed ID: 31511695	2019
CAR T cell viability release testing and clinical outcomes: is there a lower limit? Blood\| PubMed ID: 31554634	2019
T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood advances\| PubMed ID: 31575532	2019
Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. JCI insight\| PubMed ID: 31672936	2019
A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells. Blood\| PubMed ID: 31703119	2020
Author Correction: Targeting cardiac fibrosis with engineered T cells. Nature\| PubMed ID: 31723271	2019
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood advances\| PubMed ID: 31738832	2019
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 31815579	2020
CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. The Journal of clinical investigation\| PubMed ID: 31845905	2020
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. Nano letters\| PubMed ID: 31951421	2020
Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood\| PubMed ID: 31951650	2020
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction. Cancer discovery\| PubMed ID: 32001516	2020
CRISPR-engineered T cells in patients with refractory cancer. Science (New York, N.Y.)\| PubMed ID: 32029687	2020
Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability. The Journal of clinical investigation\| PubMed ID: 32069268	2020
4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling. Science signaling\| PubMed ID: 32234960	2020
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 32298202	2020
Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19. Cancer discovery\| PubMed ID: 32303509	2020
Cytokine release syndrome in severe COVID-19. Science (New York, N.Y.)\| PubMed ID: 32303591	2020
Human chimeric antigen receptor macrophages for cancer immunotherapy. Nature biotechnology\| PubMed ID: 32361713	2020
Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study. Journal of cancer research and clinical oncology\| PubMed ID: 32449004	2020
Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome. Blood\| PubMed ID: 32518951	2020
A rational mouse model to detect on-target, off-tumor CAR T cell toxicity. JCI insight\| PubMed ID: 32544101	2020
Cancer immunotherapy comes of age and looks for maturity. Nature communications\| PubMed ID: 32620755	2020
Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 32730744	2020
Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design. Molecular therapy. Methods & clinical development\| PubMed ID: 32775494	2020
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. Cell\| PubMed ID: 32961131	2020
Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. Blood advances\| PubMed ID: 33095872	2020
Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 33186691	2021
Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic-Pharmacodynamic Modeling Approaches. Journal of clinical pharmacology\| PubMed ID: 33205434	2020
Cytokine Storm. The New England journal of medicine\| PubMed ID: 33264547	2020
Nanomaterials for T-cell cancer immunotherapy. Nature nanotechnology\| PubMed ID: 33437036	2021
Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature medicine\| PubMed ID: 33547459	2021
CCR5-edited CD4 T cells augment HIV-specific immunity to enable post rebound control of HIV replication. The Journal of clinical investigation\| PubMed ID: 33571163	2021
CAR T cells targeting CD13 controllably induce eradication of acute myeloid leukemia with a single domain antibody switch. Leukemia\| PubMed ID: 33712688	2021
B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy. British journal of haematology\| PubMed ID: 33713436	2021
Cytokine Storm. Reply. The New England journal of medicine\| PubMed ID: 33882217	2021
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nature medicine\| PubMed ID: 33888899	2021
Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. Journal for immunotherapy of cancer\| PubMed ID: 34006631	2021
Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma. Frontiers in oncology\| PubMed ID: 34026647	2021
Successful prenatal therapy for anti-CD36-mediated severe FNAIT by deglycosylated antibodies in a novel murine model. Blood\| PubMed ID: 34041523	2021
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 34156874	2021
Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells. Frontiers in immunology\| PubMed ID: 34290709	2021
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. Journal for immunotherapy of cancer\| PubMed ID: 34353848	2021
BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. The Journal of clinical investigation\| PubMed ID: 34396987	2021
The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function. Cell\| PubMed ID: 34464586	2021
A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. Blood\| PubMed ID: 34521108	2022
The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 34526365	2021
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. The Lancet. Haematology\| PubMed ID: 34560014	2021
CAR T-Cells Depend on the Coupling of NADH Oxidation with ATP Production. Cells\| PubMed ID: 34571983	2021
Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells. Nano letters\| PubMed ID: 34669421	2022
Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 34675084	2022
Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy. Current opinion in immunology\| PubMed ID: 34798542	2022
An NK-like CAR T cell transition in CAR T cell dysfunction. Cell\| PubMed ID: 34861191	2021
Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function. Journal for immunotherapy of cancer\| PubMed ID: 34937742	2021
CAR T cells produced in vivo to treat cardiac injury. Science (New York, N.Y.)\| PubMed ID: 34990237	2022
Decade-long leukaemia remissions with persistence of CD4 CAR T cells. Nature\| PubMed ID: 35110735	2022
Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers. Immunity\| PubMed ID: 35263570	2022
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nature medicine\| PubMed ID: 35288695	2022
Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues. Nature cancer\| PubMed ID: 35314826	2022
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature medicine\| PubMed ID: 35314843	2022
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood advances\| PubMed ID: 35349631	2022
Next-Generation CAR T-cell Therapies. Cancer discovery\| PubMed ID: 35417527	2022
Engineered cellular immunotherapies in cancer and beyond. Nature medicine\| PubMed ID: 35440724	2022
A phase I trial of cyclosporine for hospitalized patients with COVID-19. JCI insight\| PubMed ID: 35536669	2022
Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Science advances\| PubMed ID: 35675405	2022
Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature\| PubMed ID: 35676488	2022
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 35705524	2022
CAR T-cell Therapy Meets Clonal Hematopoiesis. Blood cancer discovery\| PubMed ID: 35896010	2022
Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 35972732	2022
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma. Blood cancer discovery\| PubMed ID: 36026513	2022
Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nature medicine\| PubMed ID: 36253610	2023
Off-the-shelf CAR T cells to treat cancer. Cell research\| PubMed ID: 36329201	2022
In vivo gene immunotherapy for cancer. Science translational medicine\| PubMed ID: 36350990	2022
Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. Blood\| PubMed ID: 36351239	2023
Publisher Correction: Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature\| PubMed ID: 36380037	2022
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy. Blood cancer discovery\| PubMed ID: 36413381	2023
CAR T therapy extends its reach to autoimmune diseases. Cell\| PubMed ID: 36423579	2022
Author Correction: Decade-long leukaemia remissions with persistence of CD4 CAR T cells. Nature\| PubMed ID: 36477542	2022
Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. Cancer cell\| PubMed ID: 36513049	2022
Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma. Science advances\| PubMed ID: 36630514	2023
Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 36641624	2023
Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 36920923	2023
The Unlikely Development of CAR T Cells: a Brief History and Prospects for the Future. The Keio journal of medicine\| PubMed ID: 36967127	2023
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. bioRxiv : the preprint server for biology\| PubMed ID: 36993359	2023
Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma. Blood advances\| PubMed ID: 37058474	2023
Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. bioRxiv : the preprint server for biology\| PubMed ID: 37090547	2023
Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors. Cancer research\| PubMed ID: 37115855	2023
CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood advances\| PubMed ID: 37171449	2023
Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 37312454	2023
T-cell Therapies Targeting Multiple Cancer Antigens: The Power of Many. Cancer immunology research\| PubMed ID: 37347991	2023
Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma. Cancer research communications\| PubMed ID: 37377890	2023
CAR T therapy beyond cancer: the evolution of a living drug. Nature\| PubMed ID: 37495877	2023
Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering. Advanced healthcare materials\| PubMed ID: 37602495	2023
Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nature communications\| PubMed ID: 37607999	2023
Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy. Blood\| PubMed ID: 37616575	2024
Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function. Cancer immunology research\| PubMed ID: 37649085	2023
Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Science translational medicine\| PubMed ID: 37651540	2023
Swiss army knife T cell: one T cell many tumor targets. Cell research\| PubMed ID: 37666977	2024
Beyond youth: Understanding CAR T cell fitness in the context of immunological aging. Seminars in immunology\| PubMed ID: 37729825	2023
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer. Nature cancer\| PubMed ID: 37735588	2023
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity\| PubMed ID: 37776850	2023
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. Cell\| PubMed ID: 37794590	2023
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nature medicine\| PubMed ID: 38195751	2024
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nature medicine\| PubMed ID: 38266761	2024
Adoptive cellular therapy after hematopoietic stem cell transplantation. American journal of hematology\| PubMed ID: 38269484	2024
Long-term stability of clinical-grade lentiviral vectors for cell therapy. Molecular therapy. Methods & clinical development\| PubMed ID: 38282894	2024
ZFP36 disruption is insufficient to enhance the function of mesothelin-targeting human CAR-T cells. Scientific reports\| PubMed ID: 38326511	2024
Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager. Nature biomedical engineering\| PubMed ID: 38378820	2024
Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia. Blood advances\| PubMed ID: 38386999	2024
Enhancing chimeric antigen receptor T cell therapy by modulating the p53 signaling network with Δ133p53α. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 38408246	2024
Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy. Advanced materials (Deerfield Beach, Fla.)\| PubMed ID: 38419362	2024
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results. Nature medicine\| PubMed ID: 38480922	2024
Author Correction: Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager. Nature biomedical engineering\| PubMed ID: 38491330	2024
IL7 increases targeted lipid nanoparticle-mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 38513098	2024
Author Correction: Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues. Nature cancer\| PubMed ID: 38605236	2024
CAR T-cell Resistance to Oncogenic Transformation. Blood cancer discovery\| PubMed ID: 38713827	2024
Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation. Nature communications\| PubMed ID: 38729924	2024
The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion. Nature communications\| PubMed ID: 38730243	2024
Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma. Journal for immunotherapy of cancer\| PubMed ID: 38834201	2024
Future perspectives on engineered T cells for cancer. Trends in cancer\| PubMed ID: 38853073	2024
Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors. Cancer immunology research\| PubMed ID: 38869428	2024
Regulatory Considerations for Genome-Edited T-cell Therapies. Cancer immunology research\| PubMed ID: 39018097	2024
Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 39047033	2024
Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance. Nature reviews. Cancer\| PubMed ID: 39048767	2024
CAR T cell combination therapies to treat cancer. Cancer cell\| PubMed ID: 39059390	2024
Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nature reviews. Rheumatology\| PubMed ID: 39107407	2024
Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases. Cell\| PubMed ID: 39241743	2024
Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature\| PubMed ID: 39322664	2024
Cytokine-mediated CAR T therapy resistance in AML. Nature medicine\| PubMed ID: 39333315	2024
Beyond the blood: expanding CAR T cell therapy to solid tumors. Nature biotechnology\| PubMed ID: 39533105	2025
CAR T cells in autoimmune disease: On the road to remission. Immunity\| PubMed ID: 39549694	2024
Stem Loop Mediated Transgene Modulation in Human T Cells. ACS synthetic biology\| PubMed ID: 39642942	2024
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nature medicine\| PubMed ID: 39833408	2025
Assessing the oncogenic risk: the long-term safety of autologous chimeric antigen receptor T cells. Lancet (London, England)\| PubMed ID: 40023653	2025
From concept to cure: The evolution of CAR-T cell therapy. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 40070120	2025
LOXHD1 is an oncofusion-regulated antigen of ewing sarcoma. Scientific reports\| PubMed ID: 40234527	2025
Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors. Nature cancer\| PubMed ID: 40234680	2025
CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy. Journal for immunotherapy of cancer\| PubMed ID: 40246579	2025
CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target. Cancer immunology research\| PubMed ID: 40298385	2025
Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease-engineered T cells. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 40324075	2025
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure. The New England journal of medicine\| PubMed ID: 40334157	2025
Cellular gene therapy access in Africa: a multifactorial feasibility analysis for implementation. Cytotherapy\| PubMed ID: 40377510	2025
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial. Nature medicine\| PubMed ID: 40451950	2025
Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials. Journal for immunotherapy of cancer\| PubMed ID: 40480658	2025
Author Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial. Nature medicine\| PubMed ID: 40500416	2025
In vivo CAR T cell generation to treat cancer and autoimmune disease. Science (New York, N.Y.)\| PubMed ID: 40536974	2025
The next innovations in chimeric antigen receptor T cell immunotherapies for cancer. Cytotherapy\| PubMed ID: 40542808	2025
Enhanced CAR T-Cell Therapy for Relapsed Lymphoma. Reply. The New England journal of medicine\| PubMed ID: 40768731	2025
The senescence-inhibitory p53 isoform Δ133p53α: enhancing cancer immunotherapy and exploring novel therapeutic approaches for senescence-associated diseases. GeroScience\| PubMed ID: 40770529	2025
Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM. Frontiers in immunology\| PubMed ID: 40821779	2025
Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer. Cell reports. Medicine\| PubMed ID: 40829595	2025
From bench to bloodstream: Lipid nanoparticles drive on-demand CAR-T cells. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 40907467	2025
Multiplex engineering using microRNA-mediated gene silencing in CAR T cells. Frontiers in immunology\| PubMed ID: 40918142	2025
In vivo chimeric antigen receptor (CAR)-T cell therapy. Nature reviews. Drug discovery\| PubMed ID: 41028170	2025
Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery. Nature biomedical engineering\| PubMed ID: 41034514	2025
Microenvironmental regulation of solid tumour resistance to CAR T cell therapy. Nature reviews. Immunology\| PubMed ID: 41087553	2025
CCR5-targeted allogeneic gamma-delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy. Nature biomedical engineering\| PubMed ID: 41120570	2025
IL-9 signaling redirects CAR T cell fate toward CD8 memory and CD4 cycling states, enhancing antitumor efficacy. Immunity\| PubMed ID: 41274291	2026
CAR T cells targeting C-C motif chemokine receptor 4 (CCR4) selectively deplete human Tregs ex vivo and in vivo. Blood advances\| PubMed ID: 41370186	2025
Dual-targeted ping-pong CAR T cells: Leveraging peripheral expansion to improve solid tumor immunotherapy. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 41397127	2025
Engineering single-vector logic-gated CAR T cells with transgene sizes beyond current limitations. Journal for immunotherapy of cancer\| PubMed ID: 41513407	2026
Phase I study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 41566776	2026
CD2 costimulation bridges potent CAR-induced cytolysis and durable persistence. Journal for immunotherapy of cancer\| PubMed ID: 41571300	2026